| Ticker | ARVN |
|---|---|
| ISIN | US04335A1051 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the e...
El precio actual de Arvinas, Inc. (ARVN) es de 10,44 , con una variación del 0,19%.
Arvinas, Inc. opera en el sector Healthcare, industria Biotechnology.